Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
WASHINGTON, April 20, 2015 (GLOBE NEWSWIRE) -- Today, GovLoop is proud and excited to announce the launch of GovLoop Academy (GLA), a new, free virtual training site created specifically for...
-
SILVER SPRING, Md., April 20, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes...
-
SHANGHAI, China and PALO ALTO, Calif., April 20, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of...
-
HANOVER, Md., April 20, 2015 (GLOBE NEWSWIRE) -- Hexis Cyber Solutions, Inc. (Hexis), a wholly-owned subsidiary of The KEYW Holding Corporation (Nasdaq:KEYW), and a provider of advanced cybersecurity...
-
REDWOOD SHORES, Calif., April 20, 2015 (GLOBE NEWSWIRE) -- Imperva, Inc. (NYSE:IMPV), committed to protecting business-critical data and applications in the cloud and on-premises, announced today that...
-
YOKNEAM, Israel, April 20, 2015 (GLOBE NEWSWIRE) -- Lumenis Ltd. (Nasdaq:LMNS), the world's largest energy-based medical company for surgical, ophthalmology, and aesthetic applications announced today...
-
CAMBRIDGE, Mass., April 20, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...
-
VANCOUVER, British Columbia, April 20, 2015 (GLOBE NEWSWIRE) -- Kaneh Bosm BioTechnolgy Inc. (KBB:CSE) ("Kaneh Bosm" or the "Company") is pleased to report that ongoing business development...
-
HAMPTON, N.J., April 20, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today preclinical results that further support varlilumab's expansion into combination studies with...
-
- Bavituximab Alone and in Combination with Docetaxel Elicit a Tumor-Specific Immune Response in PD-L1 Negative Tumors Extracted from NSCLC Patients - - Immune Modulating Results Consistent with...